As a result of a series of significant technological advances, nuclear magnetic resonance (NMR) spectroscopy, which only a decade ago was considered to be largely a tool of the structural chemist, has assumed a place of growing importance as a noninvasive technique in biomedical research. Although a significant number of investigators, in a number of countries, are now using NMR spectroscopy in biochemical and physiological studies of living cells, perfused organs, and whole animals, there has not, to date, been a major conference dedicated to this subject. The proposed conference, sponsored by The New York Academy of Sciences, will focus exclusively on high-resolution NMR spectroscopy in the study of biochemical metabolic regulation and bioenergetics in vivo in experimental animal models, in whole perfused organs, and in intact cells and on the application the technique in the clinic. The importance of this conference on physiological NMR spectroscopy lies in its emphasis on the biological and clinical problems that this noninvasive technique is uniquely capable of addressing and solving. A new generation of high field spectrometers suitable for whole body or perfused organ NMR studies is becoming increasingly available as universities and other research institutions continue to commit appreciable portions of their research budgets to this technique; thus, it seems imperative at this point to build up close interactions between the NMR specialists on one hand and biochemists, physiologists, pharmacologists, toxicologists, and clinician/researchers on the other. Consequently, the goals of the proposed conference include: (1) to provide a timely forum for summarizing the current development of this rapidly emerging field with respect to both basic physiological investigations and methods for extending these studies into the clinic; and (2) to identify areas, such as potential medical applications, where in vivo NMR spectroscopy will have the greatest future impact; and (3) to foster interdisciplinary investigation so as to maximize the research capabilities of the new generation of high field biomedical NMR spectrometers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA042633-01
Application #
3184132
Study Section
Diagnostic Radiology Study Section (RNM)
Project Start
1986-07-01
Project End
1989-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Uckun, F M; Nachman, J B; Sather, H N et al. (1999) Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma 33:101-6
Uckun, F M; Sensel, M G; Sun, L et al. (1998) Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 91:735-46
Uckun, F M; Sensel, M G; Sather, H N et al. (1998) Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 16:527-35
Perentesis, J P; Waddick, K G; Bendel, A E et al. (1997) Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin Cancer Res 3:347-55
Perentesis, J P; Bendel, A E; Shao, Y et al. (1997) Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias. Leuk Lymphoma 25:247-56
Perentesis, J P; Gunther, R; Waurzyniak, B et al. (1997) In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin Cancer Res 3:2217-27
Uckun, F M; Sather, H; Gaynon, P et al. (1997) Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 27:445-57
Bendel, A E; Shao, Y; Davies, S M et al. (1997) A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Leuk Lymphoma 25:257-70
Uckun, F M; Sather, H N; Gaynon, P S et al. (1997) Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 90:28-35
Uckun, F M; Gaynon, P; Sather, H et al. (1997) Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 89:2488-93

Showing the most recent 10 out of 80 publications